Page 3 - Erick Rowinsky News Today

Biogen (NASDAQ:BIIB – Get Free Report) posted its earnings results on Wednesday. The biotechnology company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $3.45 by $0.22, Briefing.com reports. The company had revenue of $2.29 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Biogen had a net margin […]

Biogen (NASDAQ:BIIB – Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided EPS guidance of $15.00-16.00 for the period, compared to the consensus EPS estimate of $15.49. The company issued revenue guidance of decline low- to mid-single digits, compared to the consensus revenue estimate of $9.47 billion. Biogen also updated its […]

Biogen (NASDAQ:BIIB – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 15.000-16.000 for the period, compared to the consensus estimate of 15.460. The company issued revenue guidance of -. Biogen also updated its FY24 guidance to $15.00-16.00 EPS. Biogen […]

Biogen (NASDAQ:BIIB – Get Free Report) had its price objective dropped by equities research analysts at Barclays from $215.00 to $200.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would suggest a potential downside […]

Biogen (NASDAQ:BIIB – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 15.000-16.000 for the period, compared to the consensus estimate of 15.460. The company issued revenue guidance of -. Biogen also updated its FY24 guidance to $15.00-16.00 EPS. Biogen […]

Biogen (NASDAQ:BIIB – Get Free Report) announced its quarterly earnings results on Wednesday. The biotechnology company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $3.45 by $0.22, Briefing.com reports. Biogen had a return on equity of 14.91% and a net margin of 11.81%. The company had revenue of $2.29 billion […]

Biogen (NASDAQ:BIIB – Get Free Report) had its price target lowered by equities research analysts at Barclays from $215.00 to $200.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s target price points to a potential downside of 1.15% from the […]

Shares of Biogen Inc. (NASDAQ:BIIB – Get Free Report) saw strong trading volume on Wednesday . 904,201 shares traded hands during mid-day trading, a decline of 22% from the previous session’s volume of 1,159,178 shares.The stock last traded at $204.63 and had previously closed at $193.18. Wall Street Analyst Weigh In Several equities analysts have […]

Biogen Inc. (NASDAQ:BIIB – Get Free Report) shares saw strong trading volume on Wednesday . 904,201 shares changed hands during mid-day trading, a decline of 22% from the previous session’s volume of 1,159,178 shares.The stock last traded at $204.63 and had previously closed at $193.18. Wall Street Analyst Weigh In BIIB has been the topic […]

Biogen (NASDAQ:BIIB – Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share guidance of $15.00-16.00 for the period, compared to the consensus earnings per share estimate of $15.49. The company issued revenue guidance of decline low- to mid-single digits, compared to the consensus revenue estimate of $9.47 billion. […]